October 27, 2016 – Executive search firm Toft Group has placed Mark R. Willig as chief commercial officer of Rosetta Genomics Ltd. In this newly created position, Mr. Willig will be responsible for sales, marketing and market access for Rosetta Genomics’ entire portfolio of high-value diagnostic assays.
Throughout his career Mr. Willig has developed and executed global commercial and business strategies for companies ranging from leading start-ups to Fortune 500 molecular diagnostic companies. Most recently, he served as senior vice president of sales for CardioDx, Inc., a pioneer in genomic diagnostics, where he grew revenue by more than 500 percent while increasing testing volume from 21,000 tests to 150,000 tests annually.
Prior to that, he was EVP of global sales for Agendia, BV, a molecular diagnostic company that develops and markets genomic assays for early stage cancer patients. At Agendia he was responsible for the launch of their diagnostic product portfolio, which under his leadership increased revenue 140 percent to an annual run rate of $30 million. At both of these organizations Mr. Willig was responsible for securing positive medical policy and contracting with the first commercial payers.
Previously, Mr. Willig was VP of global sales at Thermo Fisher Scientific, where he had global responsibility for a $280 million dollar business unit. Mr. Willig was also the CEO at PrognostiX, a Cleveland Clinic spin-off diagnostic company.
“We are delighted to have Mark join our team at this pivotal juncture in the commercialization of our unique and evolving product portfolio,” said Kenneth A. Berlin, president and chief executive officer of Rosetta Genomics. “His proven ability to build sales platforms and drive growth for molecular diagnostic products will further enhance the commercial and clinical adoption of our first-of-its-kind microRNA classifier for indeterminate thyroid nodules as well as our urologic oncology and solid tumor offerings.”
“We are thrilled to have worked with the senior leadership of Rosetta Genomics to select Mr. Willig as chief commercial officer, and congratulate him on his new role,” said Robin Toft, the search firm’s president and CEO. “We have every confidence that he will make an exceptional contribution to the company’s continued growth and success.”
Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.
Flurry of Growth
With offices in San Francisco, San Diego and Boston, Toft Group specializes in searches for organizations in biotech, pharmaceutical, medical device, and diagnostics. The firm recently filled senior level roles for Fate Therapeutics, Agendia, OPKO Health, NanoString Technologies, and Mesa Biotech.
In recent months, the firm has seen flurry of growth. It recently opened a new office in the San Francisco Bay Area to support continued growth and customer demand. The new office is strategically situated in South San Francisco, among neighboring biotech, pharmaceutical, medical device, and digital health companies.
This expansion followed the launch of the firm’s dedicated digital health & healthcare IT search practice. This new specialized team is focused on executive and niche technical searches for digital health companies, including SaaS, PaaS, big data & analytics, mobile health, genomics, personalized medicine, patient engagement, population health management, and digital medical device companies.
Contributed by Dale M. Zupsansky, Managing Editor, Hunt Scanlon Media